Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
Sponsor: QurAlis Corporation
Summary
QRL-101-08 is a multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a novel formulation of QRL-101 in healthy participants.
Official title: A Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Formulation of QRL-101 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2026-02-02
Completion Date
2026-08-31
Last Updated
2026-02-19
Healthy Volunteers
Yes
Conditions
Interventions
QRL-101
Multiple-ascending doses of QRL-101 will be orally administered to healthy participants.
Placebo
Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
Locations (1)
ICON plc.
Groningen, Netherlands